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ABSTRACT
The role of uracil in genomic DNA has been recently
re-evaluated. It is now widely accepted to be a phys-
iologically important DNA element in diverse sys-
tems from specific phages to antibody maturation
and Drosophila development. Further relevant inves-
tigations would largely benefit from a novel reliable
and fast method to gain quantitative and qualitative
information on uracil levels in DNA both in vitro and
in situ, especially since current techniques does not
allow in situ cellular detection. Here, starting from
a catalytically inactive uracil-DNA glycosylase pro-
tein, we have designed several uracil sensor fusion
proteins. The designed constructs can be applied as
molecular recognition tools that can be detected with
conventional antibodies in dot-blot applications and
may also serve as in situ uracil-DNA sensors in cel-
lular techniques. Our method is verified on numer-
ous prokaryotic and eukaryotic cellular systems. The
method is easy to use and can be applied in a high-
throughput manner. It does not require expensive
equipment or complex know-how, facilitating its easy
implementation in any basic molecular biology lab-
oratory. Elevated genomic uracil levels from cells of
diverse genetic backgrounds and/or treated with dif-
ferent drugs can be demonstrated also in situ, within
the cell.
INTRODUCTION
Uracil, one of the nucleic acid bases present in RNA, is usu-
ally considered to be a mistake when appearing in DNA
(1). Two independent pathways may lead to the presence
of uracil in DNA. On the one hand, hydrolytic deamina-
tion of cytosine within the DNA, a rather frequent event,
results in numerous uracil moieties, which are mutagenic
since these replacements, if left unrepaired, will lead to an
exchange of a G:C base pair to a A:U (A:T) base pair (2).
On the other hand, most polymerases cannot distinguish
between deoxyuridine and deoxythymidine and will read-
ily incorporate either of these two building blocks depend-
ing on the ratio of cellular dUTP and dTTP pools (3). The
nucleotide pool is usually sanitized by dUTPases (in most
cases, these enzymes are encoded by the dut gene), an en-
zyme family conserved from bacteria to human, to avoid
such thymine-replacing uracil incorporation events (4–7).
Genomic uracil is specifically recognized by representatives
of the uracil-DNA glycosylase superfamily (UDG), cleav-
ing the N-glycosidic bond between the pyrimidine ring and
deoxyribose and resulting in apyrimidinic (AP) sites that are
further processed by base excision repair (8,9). UNG, one
of the four UDGs found in mammalian cells, specifically
excise uracil bases from both double-stranded (dsDNA)
and single-stranded DNA (ssDNA). In vitro the enzyme re-
moves uracil in the order of preference ssU>U:G>>U:A
(10–13). UNGactivity is somewhat affected by the sequence
context, having a slightly different affinity for uracil in A/T
rich regions compared toG/C rich environment (12,14–16).
To a lesser extent, bases formed from cytosine oxidation are
also substrates of UNG (5-hydroxyuracil, isodialuric acid
and alloxan; the latter only recognized by the human en-
zyme) (17,18). With a slower rate, 5-fluorouracil is also pro-
cessed, however other larger 5-halouracils (like BrdU) are
not recognized (19,20). A growing number of results show
thatUNG is somewhat capable of bindingAP sites, but with
a lower affinity compared to genomic uracil (14,21–23). No
activity has been detected against normal DNA bases or
against uracil in RNA (13) since RNA is excluded from
the DNA-binding pocket due to unfavorable steric reasons
(24,25).
Fine-tuned regulation of nucleotide pools is also of key
importance for genomic stability. Inhibitors targeting path-
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ways involved in proper dUTP/dTTP pool maintenance,
such as the de novo thymidylate biosynthesis pathways, in-
duce thymine-less cell death and are a focus of cancer treat-
ment (26). Importantly, genomic uracil may also appear un-
der normal physiological conditions. In the most extreme
cases of specific bacteriophages, such as in Bacillus sub-
tilis PBS1 and PBS2 phages, and the Yersinia enterocol-
itica R1–37 phage, the phage DNA contains deoxyuri-
dine but no deoxythymidine (27–30). Uracil in DNA was
implicated as a key factor in B lymphocyte function dur-
ing somatic hypermutation and class-switch recombination
(31–33). The surprisingly high uracil content (estimated as
>25 000 uracil/million bases) of reverse-transcribed HIV
genomicDNAhas been suggested to play an important role
in the viral life cycle (34). DNA from fruit fly larvae and pu-
pae also contains highly elevated levels of uracil (200–2000
uracil/million bases) (35,36).
As summarized above, several different fields in biol-
ogy from phage genetics to lentiviral infection mechanisms,
from antibody maturation and Drosophila development to
chemotherapeutic approaches in cancer treatment heavily
rely on genomic uracil occurrence. Hence, a reliable, fast,
cheap and easy method to gain quantitative and qualitative
information on uracil levels in DNA is of high importance
for in vitro and in vivo studies. Currently available genomic
uracil quantification methods vary in specificity, sensitiv-
ity and price. Even though LC/MS/MS based methods are
sensitive, they need laborious, excessive sample preparation
that involves nucleotide or uracil hydrolysis of the samples
(37–42). Chemical modification of uracil moieties to en-
hance detection also provides a highly sensitive method but
needs several steps in sample preparation (43,44). Real-time
polymerase chain reaction (PCR)-based techniques reflect
the uracil content only on a limited DNA fragment, and to-
tal genomic uracil content is calculated as an extrapolation
based on the assumption that uracil residues are evenly dis-
tributed throughout the genome (45) –– although this may
not be always the case.
Most techniques reported to date that aim to quantify ge-
nomic uracil levels excise uracil from DNA during the pro-
cess and do not allow in situ cellular detection. Interestingly,
for detection of numerous other non-orthodox DNA bases
such as 5-methylcytosine (46), 5-hydroxymethylcytosine
(47), 5-hydroxymethyluracil (48), thymine dimers (49), 8-
oxo-guanine (50) and 8-nitroguanine (51), antibodies have
been described. To our knowledge, no such method has yet
been reported for the uracil moieties in DNA.
In the present work, we therefore aimed at design-
ing a uracil sensor by applying a catalytically inactive
UNG uracil-DNA glycosylase, which is capable of bind-
ing to but not excising uracil (22). The uracil-recognizing
UNG sensor was designed in such a way that it can be de-
tected either with conventional antibodies in dot-blot ap-
plications or also in situ using an immunocytochemical ap-
proach. Our method is a relative quantification approach
that delivers the sensitivity of MS based approaches, reach-
ing a femtomol uracil detection limit. It may also be de-
veloped further as a ChiP like approach to gain position-
and sequence-specific information on genomic uracil con-
tent. Performance of the herein described uracil sensor has
been analyzed in dot-blot and immunocytochemical ap-
proaches, using prokaryotic CJ236 Escherichia coli [dut−,
ung−] or BL21(DE3) ung-151 E. coli [ung-] and also eu-
karyotic (Drosophila and human) cell lines with altered base
excision repair background (36,52). We have also analyzed
cells treated with several different chemotherapeutic drugs,
known to interfere with thymidylate biosynthesis and lead-
ing to increased uracil content in DNA. Our results are in
good agreement with current reports from the literature ver-
ifying that our method is sensitive, cost-effective and ade-
quate.
MATERIALS AND METHODS
Plasmid constructs and cloning
Human uracil-DNA glycosylase 2 (UNG2) cDNA was
a generous gift of Professor Salvatore Caradonna (De-
partment of Molecular Biology, University of Medicine
and Dentistry of New Jersey) and was cloned into the
XhoI/KpnI sites of the pDsRed-Monomer-N1 vector
(Clontech, Mountain View, CA, USA), as described pre-
viously (53). DsRed-fused UNG2 was further PCR am-
plified and cloned into NdeI/XhoI sites of the vector
pET-20b (Novagen, Merck Millipore, Billerica, MA, USA)
with primers UNG F and UNG R (Supplementary Ta-
ble S1). Point mutations (D154N and H277N) were cre-
ated by the QuickChange mutagenesis method (Strata-
gene, Santa Clara, CA, USA) (with primers D154N F,
D154N R and H277N F, H277N R respectively). UNG2
(D154N and H277N) lacking the first 84 amino acid
from its N-terminus (UNG) was PCR amplified (with
primers 1×FLAG F, 3×FLAG F and 1×/3×FLAG R)
and was cloned into the NdeI/XhoI sites of the vector
pET-15b (Novagen) FLAG-tagged (1× or 3×) yielding
the constructs 1×FLAG-UNGand 3×FLAG-UNGre-
spectively. Constructs UNG-DsRed and FLAG-UNG-
DsRed were PCR amplified (with primers 1×FLAG Ds F,
Ds F andDs R) and cloned into theNdeI/XhoI sites of the
vector pET-20b. The vector expressing the human codon
optimalized UGI along with GFP (pLGC-hUgi) (54) was
a kind gift of Michael D. Wyatt (South Carolina College
of Pharmacy, University of South Carolina). Primers used
in this study were synthesized by Eurofins MWG GmbH
(Ebersberg, Germany) and are summarized in Supplemen-
tary Table S1. All constructs were verified by sequencing at
Eurofins MWGGmbH.
Cell culture and transfection
The MLH1-deficient (a mismatch repair deficient) human
colorectal adenocarcinoma cell line, HCT116, was pur-
chased from the European Collection of Cell Cultures
(ECACC, Salisbury, UK). Mouse embryonic fibroblast
(MEF) cells lacking functional UNG (55) were a generous
gift from Dr Hilde Nilsen (University of Oslo). HCT116
cells were cultured in McCoy’s 5A medium (Gibco, Life
Technologies, Carlsbad, CA, USA) while MEF cells in
DMEM/F12 HAM (Sigma); supplemented with 50 g/ml
Penicillin-Streptomycin (Gibco) and 10% FBS (Gibco) in
a humidified 37◦C incubator with 5% CO2 atmosphere.
Schneider S2 cells (derived from Drosophila melanogaster)
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were purchased from Gibco and were cultured in Schnei-
der Insect Medium (Sigma) supplemented with 10% FBS
(Gibco) and 50 g/ml Penicillin-Streptomycin (Gibco) and
kept in a 26◦C incubator.
HCT116 cells were transfected with FuGENER© HD
(Promega, Madison, WI, USA) in T25 tissue culture flasks
according to the manufacturer’s recommendation. For im-
munocytochemistry MEF cells were transfected in a 6-well
plate with 4 g of normal pEGFP-N1 (purified from XL1-
Blue [dut+, ung+] E. coli cells) or uracil-rich pEGFP-N1
vector (purified from CJ236 [dut−, ung−] E. coli cells) and
12 l FuGENER© HD transfection reagent according to
the recommendation of the manufacturer. After 16 h cells
were thoroughly trypsinized and washed with phosphate
buffered saline (PBS) extensively (to wash away extracellu-
lar plasmid aggregates attached to the cell surface) and fi-
nally splitted onto 24-well plates containing poly-L-lysine
coated cover glasses.
Treatment of cells, DNA isolation and purification
Plasmid DNA. pEGFP-N1 plasmid (Clontech) was trans-
formed into XL1-Blue [dut+, ung+] (Stratagene) or CJ236
[dut−, ung−] (NEB, Ipswich, MA, USA) E. coli strains.
Cell cultures were grown for 16 h in Luria broth (LB) me-
dia supplemented with kanamycin at 37◦C, and the plas-
mids were purified using PureYieldTM Plasmid Midiprep
Kit (Promega) according to the instructions of the manu-
facturer.
Genomic DNA. XL1-Blue, BL21(DE3) ung-151 (56) and
CJ236 E. coli strains were propagated in LB media at 37◦C
andwere harvested at log-phase (A600nm = 0.5). BL21(DE3)
ung-151 cells were also grown either in the presence of
30.7 M 5-fluoro-2′-deoxyuridine (5FdUR) or 200 M 2′-
deoxyuridine (dUR) or in the presence of both drugs. Ge-
nomic DNA was purified with MasterPureTM DNA Purifi-
cation Kit (Epicentre, Madison, WI, USA), followed by an
additional purification with the Genomic DNA Clean &
Concentrator Kit (ZYMO Research, Irvine, CA, USA) us-
ing the recommendations of the manufacturer. Drosophila
Schneider S2 cells were grown either in the absence or
presence of 100 M 5FdUR, 500 M dUR or 10 M
methotrexate (MTX), 100 nM raltitrexed (RTX), 500 M
dUR for 48 h. Genomic DNA of S2 cells was purified as
above. Forty hours before treatment, HCT116 cells were
transfected either with the UGI-GFP expressing vector or
with an empty vector expressing GFP alone (pEGFP-N1).
Both transfected and non-transfected cells were grown for
an additional 48 hours in the presence or absence of 20 M
5FdUR before collecting them for genomic DNA purifica-
tion described as above.
Recombinant protein production
All UNG constructs were expressed in the E. coli
BL21(DE3) ung-151 strain and purified using Ni-NTA
affinity resin (Qiagen, Hilden, Germany). Transformed
cells growing in LB medium were induced at A600nm =
0.6 with 0.6 mM isopropyl--D-1-thiogalactopyranoside
(IPTG) for 24 h at 18◦C. Cells were harvested and lyzed in
lysis buffer (50 mM TRIS·HCl, pH = 8.0, 300 mM NaCl,
0.5 mM ethylenediaminetetraacetic acid (EDTA), 0.1% Tri-
ton X-100, 10 mM -mercaptoethanol, 1 mM phenyl-
methylsulfonyl fluoride, 5 mM benzamidine, 1×cOmplete
ULTRATM EDTA free protease inhibitor cocktail tablet
(Roche), 0.1 mg/ml lysozyme, 0.1 mg/ml DNase (Sigma,
St. Louis, MO, USA) and 0.01 mg/ml RNAse A (Invit-
rogen, Carlsbad, CA, USA)) assisted with sonication. Cell
debris was pelleted by centrifugation at 20 000 × g for 30
min. Supernatant was applied onto a Ni-NTA column and
washedwith a set of washing buffers: low salt buffer (50mM
HEPES, pH= 7.5, 30mMKCl, 5mM -mercaptoethanol),
high salt buffer (50 mMHEPES, pH = 7.5, 300 mMKCl, 5
mM -mercaptoethanol) and very high salt buffer (50 mM
HEPES, pH= 7.5, 500mMNaCl, 40mM Imidazole, 5 mM
-mercaptoethanol). UNG constructs were finally eluted
with elution buffer (50 mMHEPES, pH= 7.5, 30 mMKCl,
300mM imidazole, 5mM-mercaptoethanol) and dialyzed
against the following buffer: 30 mM Tris·HCl, pH = 7.4,
140 mM NaCl, 0.01% Tween-20, 1 mM EDTA, 15 mM -
mercaptoethanol.
Assay for testing UNG activity
A total of 150 ng of SmaI (NEB) linearized pEGFP-N1 or
uracil-rich pEGFP-N1 vector was incubated with 0.02 g
of each UNG constructs (hUNG2-DsRed WT, hUNG2-
DsRed, 1×-Flag-UNG, 3×-Flag-UNG, Flag-UNG-
DsRed,UNG-DsRed) for 1 h at 37◦C in a final volume of
11 l, in Endo IV buffer (50 mM Tris-acetate (pH 7.5), 50
mM KCl, 1 mM EDTA, 0.05% Triton X-100; Fermentas,
Waltham, MA, USA). One unit of Endonuclease IV (Fer-
mentas) was added to the reaction mixture and was further
incubated for 1 h at 37◦C. Endonuclease IV (Endo IV) is
apurinic/AP endonuclease that will hydrolyse AP sites in
DNA. AP sites are cleaved at the phosphodiester bond that
is 5′ to the lesion leaving a hydroxyl group at the 3′ terminus
and a deoxyribose 5′-phosphate at the 5′ terminus. UNG
and Endo IV treatment leads to nicks in the phosphodiester
backbone of the DNA, resulting in extensive fragmenta-
tion of uracil-rich DNA. Reaction was stopped by adding 4
l of inactivation mixture containing 2.5% sodium dodecyl
sulfate, 2.5 mg/ml Proteinase K (Sigma) and 1.5× concen-
trated DNA Loading Dye (Fermentas). Standard agarose
gel electrophoresis was performed in a 1% gel.
Electrophoretic mobility shift assay (EMSA)
A total of 100 ng of SmaI (NEB) linearized pEGFP-
N1 or uracil-rich pEGFP-N1 vector was incubated with
a series of two-fold dilution of the different UNG con-
structs (hUNG2-DsRed WT, hUNG2-DsRed, 1×-Flag-
UNG, 3×-Flag-UNG, Flag-UNG-DsRed, UNG-
DsRed) starting with 1g of protein, for 5min at room tem-
perature inUNGbuffer (30mMTRIS·HCl; 140mMNaCl;
0,01%Tween-20; 1mMEDTA; 15mM-mercaptoethanol;
pH = 7.4). Standard agarose gel electrophoresis was per-
formed in a 0.75% gel.
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Dot-blot based assay for quantification of DNA
Genomic DNA isolated from CJ236 E. coli strain [dut−,
ung−] (in log phase) served as a uracil standard. A total
of 5 ng of this genomic DNA was diluted into 2 g of
ultrapure salmon sperm DNA as an inert carrier (Invitro-
gen), which was kept constant during the two-third dilu-
tion series of this standard. The two-third serial dilutions
for XL1-Blue, BL21(DE3) and BL21(DE3) ung-151 E. coli
samples started with 1 g of DNA mixed into 1 g of car-
rier salmon spermDNA. In case of samples derived from S2
andHCT116 cells 0.6g of their genomicDNAwas diluted
into 1.4 g of carrier salmon sperm DNA. In every case
the 2 g total DNA content was kept constant with salmon
sperm DNA. DNA samples were spotted onto a prewetted
positively charged nylon membrane (Amersham Hybond-
Ny+;GEHealthcare, Little Chalfont,UK) using a vacuum-
driven microfiltration apparatus (Bio-Dot, Bio-Rad, Her-
cules, CA, USA). After 10 min of air-drying, immobiliza-
tion of DNAwas performed with 2 h of incubation at 80◦C.
Membrane was blocked by a 15 min incubation in blocking
buffer: ETBS-T (25 mM Tris·HCl, pH = 7.4, 2.7 mM KCl,
137 mMNaCl, 1 mM EDTA, 0.05% Tween-20) containing
100 g/ml salmon sperm DNA, 5% non-fat milk powder
and 10 mM -mercaptoethanol. Membrane was incubated
with the 3×-Flag-UNG construct (18.1 g/ml) in block-
ing buffer overnight at 4◦C. After several washing steps
with ETBS-T, anti-Flag M2 antibody (Sigma) was added
for 1 h at room temperature (1:2000 dilution in ETBS-T
with 5% non-fat milk powder). After washing the mem-
branes, horseradish peroxidase coupled secondary antibody
was applied (Sigma). Immunoreactive bands were visual-
ized by enhanced chemiluminescence reagent (GE Health-
care, Buckinghamshire, UK) and 16 bit images were cap-
tured by a BioRad ChemiDocTM MP Imaging system. Den-
sitometry was done using ImageJ 1.48p software (National
Institutes of Health, Bethesda, MD, USA). Normalized in-
tensity values were calculated by adjusting the raw inten-
sity values for the background originating from the carrier
salmon sperm DNA.
The average molar mass of a nucleotide inE. coli (ME.coli)
or D. melanogaster (MD.melanogaster) genomic DNA was cal-
culated with the following form:
M
[ g
mol
] = GC%2 × (MdGMP + MdCMP − 2MH2O)+
1−GC%
2 × (MdAMP + MdTMP − 2MH2O)
where MdGMP = 347.2 g/mol, MdCMP = 307.2 g/mol,
MdAMP = 331.2 g/mol, MdTMP = 322.2 g/mol, MH2O =
18.0 g/mol, are the respectivemolecularweights of the given
compounds; dGMP-dCMPpercentage (GC%) of theE. coli
genome is 50.7% and is 42.1% for D. melanogaster (based
on NCBI genome database, average of reference genomes).
Calculated values were 308.95 g/mol and 308.90 g/mol for
E. coli (ME.coli) and D. melanogaster (MD.melanogaster), re-
spectively. The very slight difference between ME.coli and
MD.melanogaster was neglected during further analysis.
In each dot of the standard samples, the mass of non-
carrier uracil-containing DNA was known and termed as
mdot, stand. The number of DNA nucleotides present in each
dot of the standard samples were calculated using the fol-
lowing form: nE. coli = mdot, standME. coli . The number of deoxyuri-
dine nucleotides were calculated using the previously de-
termined uracil content of genomic DNA isolated from log
phase culture of CJ236 [dut−, ung−] E. coli, i.e. 6580±174
deoxyuridine/million nucleotide (45). The following equa-
tion gives the amount of uracil in each dot of the standard
sample (nU, standard):
nU,standard = 6580/1000000 × nE. coli
Calibration curve from the dilution of the standard was vi-
sualized the following way for quantification: the amount
of uracil in each dot of the standard samples (nU, standard)
were plotted against the corresponding normalized inten-
sity values (Inorm, standard). Values were fitted with a poly-
nomial with the least order that provided a fit with R2 ≥
0.99. The number of uracilmillion bases in the ‘unknown’ genomic DNAs
were determined by interpolating their normalized inten-
sities (Inorm, unknown) in the calibration plot based on the
amount of DNA applied (mdot, unknown).
Statistics
Statistical analysis was carried out by InStat 3.05 software
(GraphPad Software, San Diego CA, USA) using the non-
parametric Kruskal–Wallis test or one-way ANOVA test
with Student-Newman-Keuls multiple comparison post-
hoc test when samples passed equal variance (Bartlett’s test)
and normal distribution tests (Kolmogorov–Smirnov test).
Differences were considered statistically significant at P <
0.05.
Western blot
Cells were collected, washed with PBS, and resuspended in
lysis buffer (50 mM TRIS·HCl pH = 7.4; 140 mM NaCl;
0,4% NP-40; 2 mM dithiothreitol (DTT); 1 mM EDTA,
1 mM phenylmethylsulfonyl fluoride; 5 mM benzamidin,
1×cOmplete ULTRATM EDTA free protease inhibitor
cocktail tablet (Roche)). Cell lysis was assisted with sonica-
tion. Insoluble fraction was removed by centrifugation (20
000 × g × 15 min at 4◦C). Protein concentration was mea-
sured with BioRad Protein Assay to ensure equivalent total
protein load per lane. Proteins were resolved under dena-
turing and reducing conditions on a 12% polyacrylamide
gel and transferred to PDVF membrane (Immobilon-P,
Merck Millipore, Billerica, MA, USA). Membranes were
blocked with 5% non-fat dried milk and were developed
against GFP (1:2000, Molecular probes, Life Technologies,
Carlsbad, CA, USA) and actin (1:500, Sigma) for load-
ing control. After applying horseradish peroxidase coupled
secondary antibodies (Amersham Pharmacia Biotech), im-
munoreactive bands were visualized by enhanced chemilu-
minescence reagent (GE Healthcare) and images were cap-
tured by a BioRad ChemiDocTM MP Imaging system.
Staining uracil residues in E. coli genomic DNA
Immunofluorescence staining was done based on the work
of (57) with modifications. Briefly, 500 l of XL1-Blue
[dut+, ung+] and CJ236 [dut−, ung−] E. coli cells were col-
lected in log-phase (A600nm = 0.5), by centrifuging them at
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Figure 1. Schematics of the used constructs for uracil detection. In our constructs, human UNG2 was used as the uracil sensor core domain. During in
vitro quantification and for in situ detection, a double mutant UNG2 was created (D154N and H277N, mutated sites indicated with black lines within the
schematics of the protein domains). This mutant is catalytically inactive but is still capable of binding uracil moieties in DNA (cf text for more details). The
N-terminal 84 residues, responsible for the binding to RPA and PCNA, were also removed (UNG) to prevent non-specific binding. The UNG uracil
recognizing core was fused to epitope tags (1×/3×FLAG, Au1) for immunodetection, DsRed-monomer for direct fluorescent detection and to His-tag for
affinity purification.
7000 × g for 5 min and were washed with PBS. Cells were
fixed with Carnoy’s fixative (ethanol:acetic acid:chloroform
= 6:3:1) for 20 min at 4◦C. Rehydration was performed as
following: washing with 1:1 ethanol:PBS, 3:7 ethanol:PBS
and finally incubating in PBS containing 0.05% Triton X-
100 (PBST) for 5 min. Cells were washed once with GTE
buffer (50 mM glucose, 20 mM Tris, pH = 7.5 and 10 mM
EDTA), and finally resuspended in GTE buffer containing
10 mg/ml lysozyme (Sigma) for 5 min. The suspension was
applied onto poly-L-lysine coated cover glasses for an ad-
ditional 5 minutes, excess fluid was drained and cells were
left to air-dry. Cells were washed with PBST for 10 min and
were blocked in blocking buffer (5% BSA, in PBST) for 15
min. Uracil residues were visualized by applying 4.64g/ml
of the Flag-UNG-DsRed construct in blocking buffer,
overnight at 4◦C. After several washing steps with PBST,
anti-FLAGM2 antibody (Sigma) was applied (1:2000 dilu-
tion) for 1 h in a blocking buffer. FLAG epitope was visual-
ized by applying Alexa 488 conjugated secondary antibody
(1:1000, Molecular Probes). Cells were counterstained with
1 g/ml DAPI (4′,6-diamidino-2-phenylindole, Sigma) and
embedded in FluorSaveTM Reagent (Calbiochem, Merck
Millipore, Billerica, MA, USA). Images were acquired with
a Zeiss LSCM 710 microscope using a 63× NA = 1.4 Plan
Apo objective.
Staining uracil residues of extrachromosomal plasmids in
MEF cells
Cells were washed with prewarmed (37◦C) phosphate
buffered saline (PBS, pH = 7.4) and were fixed with
ice cold Carnoy’s fixative (ethanol:acetic acid:chloroform
= 6:3:1) for 20 minutes at 4◦C. Rehydration was per-
formed as following: washing step with 1:1 ethanol:PBS, 3:7
ethanol:PBS, finally with PBS for 5 min. Epitope unmask-
ing was done by applying 1 N HCl, 0.5% Triton X-100 for
15 min, after which 0.1 M Na2B4O7 (pH = 8.5) was used
for neutralization for 5 min followed by PBS washing. HCl
was used to denature DNA, allowing our UNG construct
to have better access to genomic uracil. This method is also
routinely applied when using antibodies against BrdU, do-
ing cell proliferation assays (see (58)). Blocking was done
at room temperature for 1 h in blocking buffer: 200 g/ml
salmon sperm DNA, 5% fetal goat serum (FGS), 3% fe-
tal bovine serum albumin (BSA) and 0.05% Triton X-100
in PBS. Uracil residues were visualized by applying 4.64
g/ml of the Flag-UNG-DsRed construct in blocking
buffer, overnight at 4◦C. After several washing steps with
blocking buffer, anti-FLAG M2 antibody (Sigma) was ap-
plied (1:2000 dilution) for 1 h in a blocking buffer not
containing salmon sperm DNA. FLAG epitope was visu-
alized by applying Alexa 488 conjugated secondary anti-
body (1:1000,Molecular Probes). Cells were counterstained
with 1g/mlDAPI (Sigma) and embedded in FluorSaveTM
Reagent (Calbiochem). Images were acquired with a Zeiss
LSCM 710 microscope using a 63× NA = 1.4 Plan Apo
objective.
RESULTS AND DISCUSSION
Construction and analysis of catalytically inactive uracil-
sensor proteins
Wild-type human UNG2 possesses a highly selective sub-
strate binding site for uracil and is specific for excising
uracil from DNA, with a negligible activity toward the nat-
ural DNA bases cytosine or thymine (59). The catalytically
inactive double mutant (D145N, H268N) human UNG2
preserves this highly specific and strong binding interac-
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tion with uracil-containing DNA similar to the wild-type
enzyme. (22,60). Similar Kd values were observed for the
wild-type and the double mutant enzyme for non-cleavable
substrate analogs (22). We therefore aimed at employing
this double mutant protein as a specific uracil sensor that
strongly binds to the uracil base but does not excise it from
DNA. Since our sensor relies on the characteristics of the
human UNG2, it is capable of recognizing a few derivatives
of uracil, and could also bind abasic sites (APs) but with
a lower affinity compared to genomic uracil (see details in
the Introduction). This concept, if successful, could be used
as a novel labelling method capable of recognizing genomic
uracil both in vitro using a dot-blot based method and in
situ, similarly to an immunocytochemical approach.
To obtain an even more specific UNG-based uracil-
sensor construct, we eliminated the N-terminal 84 residues
from the human UNG enzyme that comprises a recogni-
tion site for PCNA and RPA proteins (61–63), resulting
in the construct termed as UNG in the present work (cf
Figure 1, note that all constructs termed UNG harbor
the double mutationsD145N,H268N). This truncation was
deemed to be highly desirable in order to erase non-specific
protein binding while retaining similar specificity and bind-
ing characteristics as the full length form while also being
more resistant to proteolysis (10,12,64). Moreover, the lack
of the N-terminal 84 residues diminishes the need of Mg2+
for proper UNG function which is useful to lower any resid-
ual nuclease activity during the assays by applying EDTA
(10,64). We also equipped this truncated construct with dif-
ferent tags: His-tag for purification and Flag- and Au1-tags
for antibody-based detection. Further, in order to achieve
a low background through direct detection in immunocy-
tochemistry, we have attached a red fluorescent protein, the
monomeric form of DsRed, to the C-terminal end of our
construct.
In order to check the required and expected functional-
ity of our constructs, we have carried out enzyme activity
assays (as described in ‘Materials and Methods’ section).
Figure 2A confirms that the only construct showing cat-
alytic activity on uracil-rich DNA is the wild type UNG,
whereas all of our UNG constructs lack any detectable
excising activity. On the other hand, as shown on Figure 2B
and Supplementary Figure S1, all of our constructs show
preferential binding to uracil-rich as compared to normal
DNA.
Development of a dot-blot based quantitative assay for detec-
tion of genomic uracil in vitro
In testing our different constructs, we have used either just
a single (1×) or a triplicated (3×) Flag-tag form and em-
ployed them on our standard, namely the genomic DNA
isolated from log phase CJ236 [dut−, ung−] E. coli cells
for which uracil content has been previously quantified
(43,45). Figure 3 shows that the triplicated Flag-tag con-
taining UNG sensor is more sensitive in the dot-blot as-
say. This construct was therefore used in all further experi-
ments. Figure 3 also indicates that a linear response could be
reached on a series of dilutions in wide dynamic range. For
each experiment, a calibration curve was always recorded
Figure 2. Activity and uracil binding capability of the used constructs.
(A) Agarose gel electrophoresis based assay was applied to detect UNG
activity. Only the hUNG2-DsRed WT construct was active on uracil-
rich plasmid (indicated with an asterisk), which did not harbor the two
point mutations (D154N and H277N). All other constructs used in the
study do not excise uracil from DNA. (B) Uracil binding capability of the
3xFLAG-UNG construct was addressed with Electrophoretic Mobility
Shift Assay (EMSA). Increasing amount of the construct clearly shifts the
position of the linearized vector, which is more prominent in case of uracil-
rich template, indicating that the construct is capable of binding genomic
uracil moieties. We have experienced similar result with the other tested
constructs (Supplementary Figure S1).
Figure 3. Design of a standard curve for in vitro quantification of ge-
nomic uracil levels. Genomic DNA isolated from log phase growing CJ236
[dut−, ung−] Escherichia coli strain was used as a standard with well-
defined uracil-content during quantification. Applying a serial dilution of
this standard provides a wide and reproducible range for uracil quantifica-
tion. The normalized calibration curve is from four independent datasets
(n = 4), where error bars show standard errors of the mean (SEM). The
inset shows that the 3×FLAG-UNG construct is slightly more sensitive
under similar conditions, compared to the 1×FLAG-UNG construct (as
based on a 4 point two-third serial dilution, starting with 100 ng of stan-
dard genomic DNA).
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which was highly reproducible thus served as a firm basis
for our further studies.
It has been described in the literature that treatments
with drugs interfering with thymidylate biosynthesis (e.g.
5-fluorodeoxyuridine (5FdUR) (65)) can lead to consider-
ably elevated uracil levels in genomic DNA (66–68). Ac-
cordingly, Figure 4 summarizes the de novo thymidylate
biosynthesis pathway and indicates the enzymatic steps
known to be perturbed by different drugs (frequently used
in anti-cancer chemotherapy). We therefore applied such
drug treatments onE. coli cells. Figure 5 shows that the dot-
blot assay adequately reflects the expected increase in uracil
content for genomic DNA isolated from the BL21(DE3)
ung-151 E. coli strain. Although a basal higher uracil con-
tent could have been expected, the lack of the major uracil-
DNA glycosylase in the ung-151 cells in the absence of drug
treatment did not lead to any significant increase in the
genomic uracil content (4.66 ± 2.24 uracil/million bases)
compared to XL1-Blue (3.29 ± 1.74 uracil/million bases)
(cf Figure 5. This indicates that the difference, if exists, has
to be below the detection limit. Because the dUTPase en-
zyme is still present in the ung-151 cells, the dNTP pool is
not perturbed to an extent where erroneous uracil incorpo-
ration through replication is expected to occur. Thus, the
sole lack of UNGmight not be enough to create detectable
increase in genomic uracil.
Also, treating the BL21(DE3) ung-151 cells with de-
oxyuridine (dUR) alone did not change the genomic uracil
content (4.28 ± 2.05 uracil/million bases) (Figure 5). In
contrast, applying 5FdUR on exponentially growing ung-
151 cells, the dot-blot assay clearly showed an ∼10-fold in-
crease in the uracil content (39.89 ± 7.72 uracil/million
bases) (Figure 5). The same∼10-fold increase was observed
when the two drugs were applied together (35.61 ± 4.54),
arguing that the effect induced by 5FdUR is not enhanced
by dUR. The ung- background is a major factor allowing
the increase of genomic uracil content upon drug treatment,
since drug treatment of cells with a [dut+, ung+] genetic
background (either XL1 Blue or BL21(DE3) cells) did not
lead to increased uracil levels (Supplementary Figure S2).
For further experiments, we applied a eukaryotic cell
line with a ung− background. As described previously, the
ung gene is interestingly absent from D. melanogaster (69),
hence we used the Drosophila embryo-derived Schneider
S2 (termed as S2 in the present study) cell line. We have
shown that this cell line can tolerate the increased genomic
uracil content well (36), making it an optimal object for our
present work.
Figure 6 shows that dual treatment of S2 cells with
5FdUR and dUR (25.54±2.98 uracil/million bases) leads
to a significantly elevated genomic uracil content com-
pared to non-treated cells (15.68 ± 3.02 uracil/million
bases). Another drug combination of raltitrexed (RTX)
and methotrexate (MTX), targeting thymidylate synthase
(TYMS) (70) and dihydrofolate reductase (DHFR) (71), re-
spectively (cf Figure 4), also induced a significant, two-fold
increase in the genomic uracil content in S2 cells (32.18 ±
3.24 uracil/million bases). Highmethotrexate tolerance was
already suggested for the S2 cell line, with potential pertur-
bation of the relevant pathways (72). Hence, these results
Figure 4. Pathways involved in thymidine synthesis in Escherichia coli,
Drosophila melanogaster and humans. Key steps in dNTP synthesis fo-
cusing on the de novo thymidylate biosynthesis are shown (directly in-
volved enzymes underlined). Dashed arrow shows pathways only present
in E. coli. Inhibitors of the pathway are shown in red. 5FdUMP (5-
fluorodeoxyuridylate), the metabolite of 5FU and 5FdUR, along with
raltitrexed (RTX) inhibits thymidylate synthase (TYMS) while methotrex-
ate (MTX) inhibits dihydrofolate reductase (DHFR). The enzyme respon-
sible for dCTP-dCMP conversion in mammals is DCTPP1 (dCTP py-
rophosphatase 1) (78), however, using a BLAST search, no clearcut ho-
mologue could be identified in D. melanogaster, hence we did not in-
clude it in this Figure. In E. coli, the nucleoside triphosphate pyrophos-
phohydrolase MAZG is responsible for this activity (79). Abbreviations
are as follows: DCD: dCTP deaminase, DCTD: dCMP deaminase, DUT:
dUTPase, DHF: dihydrofolate, DHFR: dihydrofolate reductase, MTHF:
5,10-methylene tetrahydrofolate, NDPK: nucleoside-diphosphate kinase,
NK: nucleoside kinase, MAZG: nucleoside triphosphate pyrophospho-
hydrolase, NMPK: nucleoside monophosphate kinase, SHMT: serine hy-
droxymethyltransferase, THF: tetrahydrofolate, TYMK: dTMP kinase,
TYMS: thymidylate synthase.
are in agreement with previous literature and attest to the
applicability of our assay.
In order to test our method on human derived samples
we used HCT116, a colon carcinoma cell line. UNG defi-
ciency was achieved by applying a specific UNG inhibitor,
UGI (73,74). The expression of human codon optimalized
UGI inhibits endogenous UNG activity thus resembling
a ung−/− phenotype (68). Figure 7 shows that treating
HCT116 cells with 5FdUR after transfection with UGI
(GFP is also expressed from the vector for monitoring pur-
poses) significantly elevates genomic uracil levels (347.87 ±
84.62 uracil/million bases) compared to non-treated cells
(7.82 ± 2.82 uracil/million bases). On its own neither
5FdUR treatment nor UNG inhibition elevates genomic
uracil levels. 10.47 ± 2.82 uracil/million bases was mea-
sured for the non-treated and 10.92 ± 1.97 uracil/million
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Figure 5. Dot-blot assay for measuring genomic uracil levels of 5FdUR, dUR treated Escherichia coli cells. (A) CJ236 [dut−, ung−] E. coli genomic
DNA was used as standard for the dot-blot assay. Quantity of genomic uracil of different drug-treated (5FdUR and dUR or both) and non-treated
E. coli BL21(DE3) ung-151 samples were measured along with XL1-Blue [dut+, ung+], applied as a negative control. (B) Bar graph shows the uracil
moieties/million bases of each sample (mean values ± the standard errors of the mean). Significant incrase (*) in uracil-DNA content was only observed
using 5FdUR treatment, or the combined 5FdUR and dUR treatment as compared to non-treated cells (P < 0.05). Calculations were based on six
independent datasets (n = 6).
Figure 6. Dot-blot assay for measuring genomic uracil levels ofDrosophila Schneider S2 cells after treatment with de novo thymidylate biosynthesis pathway
inhibitors. (A) CJ236 [dut−, ung−] Escherichia coli genomic DNA was used as standard for the dot-blot assay. Genomic uracil content of different drug-
treated (5FdUR, dUR or MTX, RTX, dUR) and non-treated Drosophila S2 cells were measured. (B) Bar graph shows the uracil moieties/million bases
of each sample (mean values ± the standard errors of the mean). Both types of treatments led to significantly elevated genomic uracil levels as compared
to non-treated cells (* = P < 0.01, ** = P < 0.05). Calculations were based on six independent datasets (n = 6).
bases for the 5FdUR treated. Similarly no significant dif-
ference was measured in case of cells that were transfected
with an empty vector, expressing only GFP as control (4.17
± 1.19 for the non-treated and 7.39 ± 2.98 uracil/million
bases for the 5FdUR treated cells, respectively). These re-
sults are in good agreement with previously reported data
(cf (68)) and also highlight the importance of simultaneous
UNG inhibition alongwith drug treatments targeting the de
novo thymidylate biosynthesis pathway for effective cancer
therapy.
Application of the catalytically inactive UNG constructs for
detection of uracil in DNA in situ
Figure 8 presents that the highly uracil-rich character
of the CJ236 [dut−, ung−] E. coli cells, containing 6580
uracil/million bases, can be readily visualized via immuno-
cytochemistry using our presently developed uracil sensor
construct. Relying on the Flag-tag in our UNG con-
structs, the uracil-DNA staining is easy to detect and colo-
calizes, as expected, with the DAPI signal for DNA. It is
also important to note that the DsRed-tag may also be
used for direct visualization. Specificity of the signal is ad-
equately corroborated by lack of the staining in the XL1-
Blue [dut+, ung+] cells. Application of the UNG inhibitor
UGI (obtained from NEB) protein erases the signal, show-
ing again the specific character of our assay (Supplementary
Figure S3). The well-described UNG-UGI interaction has
been documented to prevent binding of UNG toDNA (74).
We have also attempted to use similar strategy for stain-
ing of uracil-DNA in a mammalian cellular background.
To this end, we have transfected [ung−/−] MEF cells with
plasmidDNAproduced by CJ236 [dut−, ung−]E. coli cells.
Such plasmid DNA contains ∼6580 uracil/million bases
(45) and its tolerance in the MEF cells is ensured by lack of
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Figure 7. Dot-blot assay for measuring genomic uracil levels of HCT116 cells after treatment with de novo thymidylate biosynthesis pathway inhibitors and
UNG inhibition. (A) CJ236 [dut−, ung−] Escherichia coli genomic DNA was used as standard for the dot-blot assay. (B) Genomic uracil levels of 5FdUR
treated and non-treated HCT116 cells were measured in the contex of endogenous UNG inhibition with UGI expression. (C) Bar graph shows the uracil
moieties/million bases of each sample (mean values ± the standard errors of the mean). 5FdUR treatment led to significantly elevated uracil levels only in
cells also expressing UGI (* = P < 0.05) when compared to non-treated cells. Calculations were based on four independent datasets (n = 4). (D) Western
blot showing GFP expression of cells transfected by the UGI-GFP vector and the empty vector used as a control (only expressing GFP). The membrane
were also developed against actin as a loading control.
the UNG enzyme in this mouse cell line. In this experiment,
we make use of a well-known artifactual effect of plasmid
transfection, namely that upon using high amount of plas-
mid DNA during transfection, plasmid aggregates can oc-
cur within the cells (75) (Figure 9A). We therefore worked
out our transfection experimental conditions such that to
allow the potential accumulation of intracellular plasmid
aggregates (cf ‘Materials and Methods’ section). Figure 9B
leftmost panels clearly show DAPI staining of these plas-
mid aggregates indicated by white asterisks. In case of non-
transfected cells (negative control), no plasmid aggregates
can be observed (Supplementary Figure S4). On Figure 8,
upper panels with cells transfected with uracil-rich plasmid
show positive reaction with our uracil sensor molecules, ei-
ther via Flag-tag or via direct DsRed detection. Addition-
ally as a negative control, cells transfected by normal plas-
mid (produced inXL1-Blue cells) show no staining. Further
controls are also shown in Supplementary Figure S4 where
the lack of uracil-specific staining can be observed when the
UNG-inhibitor UGI was applied.
Although these results clearly show the possibility of us-
ing our method for in situ microscopic detection, the sensi-
tivity of this staining approach needs to be developed fur-
ther to allow detection of lower uracil levels. Additional
enhancement of the signal might be expected from the ap-
plication of brighter and more stable fluorophores, such as
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Figure 8. In situ genomic uracil detection in Escherichiacoli using an immunocytochemistry approach. The genomic uracil content of CJ236 [dut−, ung−]
E. coli cells was visualized with the Flag-UNG-DsRed construct. As a negative control, XL1-Blue cells [dut+, ung+] were also used in the same staining
procedure. Only the CJ236 [dut−, ung−] E. coli sample showed staining, either detected directly through the signal of DsRed (red) or through the FLAG
epitope tag (green). DAPI was used to counterstain DNA. Scale bar represents 10 m.
Figure 9. Detection of uracil-rich and normal plasmid DNA aggregates in MEF [ung-/-] cells. (A) Schematic image of the cytoplasmic plasmid aggregates
visualized by the Flag-UNG-DsRed construct. (B) Asterisks (*) show plasmid aggregates. Only cells transfected with uracil-rich plasmids could be
visualized both through the DsRed (red) tag and the FLAG epitope tag (green). The DAPI staining is oversaturated to show the faint DAPI positive
plasmid aggregates in the cytoplasm. Scale bar represents 10 m.
nanocrystals or quantumdots (cf (76)). Our presentmethod
forms the basis for such further developments.
CONCLUSION
The workflow of the novel method described in this study is
shown schematically on Figure 10, both for the in vitro dot-
blot based detection (Figure 10A) and the in situ immuno-
cytochemical approach used for cellular detection (Figure
10B). Uracil moieties are recognized by a catalytically inac-
tive UNG sensor protein and the readout signal is enhanced
by using primary and secondary sets of antibodies. The re-
cently described novel mycobacterial uracil-DNA binding
protein may also serve as an alternative sensor framework
(77). The method is straightforward, easy to use and can be
applied in a high-throughput manner to analyze DNA from
any organism. It does not require expensive instruments or
complex know-how, facilitating its easy implementation in
any basic molecular biology laboratory. Elevated genomic
deoxyuridine content of cells from diverse genetic back-
ground and/or treated with different drugs can be demon-
strated in situ, within the cell. Direct detection is possible
through the DsRed-tagged construct, or antibodies may be
used for signal enhancement through the different epitope
tags.
Direct comparisons between values for genomic uracil
content obtained by differentmethods are far from straight-
forward (cf e.g. data for genomic DNA from CJ236 [dut−,
ung−]E. coli cells range between 3000–18 000/million bases
(38,43,45)). Hence, the truly reliable approach is to compare
relative differences induced by different cellular stages, en-
vironment and/or drug treatments using the same method.
Our present method is optimal for detecting such differ-
ences due to its ease of application, robustness and amenity
to high-throughput studies. With the dot-blot based assay,
comparative data between different organisms and differ-
ent cellular conditions are obtained fast and in a quantita-
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Figure 10. Schematics summarizing the developed in vitro quantification and in situ detection method. (A) Schematic image of the applied in vitro quan-
tification through a dot-blot approach. (B) Schematic image of the applied immunocytochemical approach for in situ uracil detection.
tive manner. Finally, a major further significance and nov-
elty in our presently proposed study is that it provides po-
tential for in situ detection of uracil-DNA within cells. To
our knowledge at least, such in situ detection has not yet
been described for uracil in DNA. Considering the numer-
ous physiological events and pathological conditions where
uracil levels in DNA are modified, our method presents
a biologically relevant tool for assessing the composition
of genomic DNA and its putative alterations during dif-
ferent cellular conditions. In this respect, we wish to point
out that our results obtained with UGI-expressing HCT116
cells simultaneously treated with 5FdUR indicates that the
combined perturbation of base-excision repair and de novo
thymidylate biosynthesis leads to a synergistic cellular re-
sponse elevating genomic uracil levels. The significance of
our proposed technique is further enhanced by the fact that
uracil detection has yet escaped the highly powerful single-
molecule real-time sequencing (SMRT) technology, as well.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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